Several early‐stage trials involving CAR T cells for renal cell carcinoma (RCC) are ongoing, assessing the feasibility of mainly two receptor tyrosine kinase targets: AXL, which plays diverse roles in tumor cell proliferation, migration, and survival (NCT03393936) and ROR2 (NCT03960060). Here, NTRK1 is linked to renal cell carcinoma.